Wegovy vs Ozempic: Same Drug, Different Brand - What to Know
Patient confusion about Wegovy vs Ozempic is among the most-searched questions in cash-pay healthcare in 2026. Both are semaglutide. The brand split is for indication-specific marketing, insurance formulary placement, and dosing range. Both are made by Novo Nordisk. Both are weekly subcutaneous injections.
At a Glance
| Dimension | Semaglutide for Weight Loss | Semaglutide for Weight Loss |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide (same molecule) |
| FDA-approved indication | Chronic weight management (obesity) | Type 2 diabetes |
| Maximum dose | 2.4 mg/week | 2.0 mg/week |
| FDA approval date | June 2021 | December 2017 |
| Retail list price (US) | ~$1,350/month | ~$1,030/month |
| Insurance coverage breadth | Limited - many plans exclude obesity | Broad - diabetes is widely covered |
| Medicare coverage | Not covered (obesity exclusion) | Covered for type 2 diabetes |
| Off-label use | Rare (labeled for obesity) | Common (off-label for weight loss) |
| Pen colors / packaging | Blue/silver/maroon pens by dose | Different color scheme; clinic-familiar |
| Dose increments | 0.25, 0.5, 1.0, 1.7, 2.4 mg/week | 0.25, 0.5, 1.0, 2.0 mg/week |
About this comparison
Wegovy and Ozempic are two different brand names for the same molecule (semaglutide), manufactured by Novo Nordisk but FDA-approved for different indications. Wegovy is approved for chronic weight management at doses up to 2.4 mg/week. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg/week. The two products are not interchangeable from a labeling standpoint but contain identical active ingredient. Off-label Ozempic prescribing for weight loss has been common despite the dose ceiling difference.
Patients with obesity (BMI 30+ or 27+ with comorbidity) seeking the on-label indication, especially if their insurance has obesity-specific coverage. Wegovy is the legally appropriate prescription for weight management.
Patients with type 2 diabetes (the labeled indication). Ozempic prescribed off-label for weight loss has been a workaround when Wegovy is not covered, though FDA labeling specifies diabetes.
Cost comparison
Retail pricing is similar at approximately $1,000-$1,350/month for either brand without insurance. Insurance coverage drives the bigger cost differential: Ozempic is much more broadly covered (diabetes is a widely-funded category) while Wegovy faces narrow obesity-specific formularies. Many patients without obesity coverage have used Ozempic off-label at lower out-of-pocket cost, though this practice has tightened as supply has constrained.
Evidence comparison
Identical molecule, identical mechanism of action. All clinical evidence for semaglutide applies to both brands. The SELECT cardiovascular outcomes trial (NEJM 2023) was done with semaglutide and the labeling for cardiovascular benefit was extended to Wegovy specifically for obesity patients with established cardiovascular disease.
Frequently asked questions
Is Wegovy the same as Ozempic? +
Both contain the same active ingredient (semaglutide). They are different FDA-approved products from the same manufacturer (Novo Nordisk) labeled for different indications. Wegovy is labeled for obesity at doses up to 2.4 mg/week; Ozempic is labeled for type 2 diabetes at doses up to 2.0 mg/week.
Why is Ozempic prescribed for weight loss if it is labeled for diabetes? +
Off-label prescribing is legal and common in US medical practice. Before Wegovy was widely available (or covered), prescribers commonly used Ozempic off-label for weight loss because it was the same molecule with broader insurance coverage. The practice has tightened as Wegovy supply expanded and as some insurers have audited off-label use.
Which is cheaper without insurance: Wegovy or Ozempic? +
Retail list prices are similar at approximately $1,000-$1,350/month without insurance. Ozempic has slightly lower list price (~$1,030) versus Wegovy (~$1,350). Manufacturer savings cards can reduce costs for patients with commercial insurance but not Medicare.
Can I switch from Ozempic to Wegovy? +
Yes. Many patients who started on Ozempic off-label for weight loss have transitioned to Wegovy as insurance coverage improved and the higher 2.4 mg dose became available. Switching is straightforward; the molecule is identical.
Does Medicare cover Ozempic or Wegovy? +
Medicare Part D covers Ozempic for type 2 diabetes (its labeled indication). Medicare does not currently cover any obesity medication including Wegovy. Legislation to expand Medicare coverage for obesity medications has been proposed multiple times but has not passed as of 2026.
Which one will I lose more weight on? +
In trials, the weight loss is dose-dependent. Wegovy at 2.4 mg/week produces approximately 14.9 percent weight loss at 68 weeks (STEP 1 trial). Ozempic at maximum 2.0 mg/week produces approximately 12-13 percent in studies of obesity off-label use. The 0.4 mg/week dose difference accounts for the slight efficacy advantage.
Is compounded semaglutide the same as Wegovy or Ozempic? +
Compounded semaglutide uses the same active molecule but is prepared by 503A pharmacies rather than manufactured by Novo Nordisk. Quality, sterility, and concentration depend on the compounding pharmacy. Following the FDA shortage list resolution in 2025, compounding has tightened. See our semaglutide guide for full regulatory detail.
Bottom line
For weight management in 2026, Wegovy is the labeled prescription and the right legal choice. Ozempic remains FDA-approved for type 2 diabetes only; off-label prescribing for weight loss has narrowed but persists in some practices. From a clinical standpoint the molecule is identical; the differences are purely in indication, dose ceiling, and insurance coverage policy.
Sources
- FDA. "Wegovy (semaglutide) injection 2.4 mg Prescribing Information." 2024. (Wegovy labeling)
- FDA. "Ozempic (semaglutide) injection Prescribing Information." 2024. (Ozempic labeling)
- Wilding JPH, et al. STEP 1 trial. New England Journal of Medicine, 2021. (Wegovy efficacy in obesity)